DV
Dividend Vision

BOLD — Boundless Bio, Inc. Common Stock

Boundless Bio, Inc. Common Stock (BOLD)

Total return is -80.1% over the past 2.4 years, 132.5 points behind SPY at 52.4%. Its deepest 1-year drawdown was 30.5%.

Boundless Bio, Inc. is a clinical-stage oncology company developing therapies that target extrachromosomal DNA to treat oncogene-amplified cancers, with its lead candidate BBI-940 currently in Phase 1/2 clinical trials for breast cancer indications. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotech development with a focus on novel cancer treatment approaches.

BOLD key facts

Asset type
Stock
Asset class
Equity
Inception date
03/28/2024
Last close
$2.83
Market cap
$56,411,688
Average volume
108961.0
Beta
0.974
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.49